RT Journal
A1 Mitka M
T1 SPeeding drug approvals
JF JAMA
JO JAMA
YR 2012
FD May 9
VO 307
IS 18
SP 1904
OP 1904
DO 10.1001/jama.2012.4001
UL http://dx.doi.org/10.1001/jama.2012.4001
AB 
The bill would amend the Food, Drug, and Cosmetic Act to require the FDA to facilitate the development and expedite the review of breakthrough drugs. These are defined as medications that are intended for a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that these medications may demonstrate substantial improvement over existing therapies.